Good News

Congratulations to Jinbo Pharma JB Protein

Won the Silver Award of

the 48th Geneva International Exhibition of Inventions

Recently, at the 48th Geneva International Exhibition of Inventions in 2021, the project "JB Protein for Cervical Cancer/AIDS Prevention" jointly researched by Shanxi Jinbo Bio-pharmaceutical Co., Ltd and Fudan University successfully won the silver award in the exhibition, indicating the innovative achievement is recognized by the world's authoritative institutions.

Cervical cancer is the reproductive system malignant tumor with the highest incidence rate and mortality among Chinese women, and the number of morbidity and mortality is increasing year by year. The study found that HPV can be detected in about 90% of cervical cancer patients, and high-risk HPV is closely related to cervical cancer. The JB Protein of Jinbo Pharma, which won the silver award at the Geneva International Exhibition of Inventions, has highly targeted inhibitory effect and specificity on HPV and AIDS HIV that cause cervical cancer, and has been patented in China, successfully realized its industrialization, and solved the international gap in anti-HPV products in the field of medical appliances.

JB Protein is a kind of bovine β-lactoglobulin modified by acid anhydride and is a virus entry inhibitor. Gel containing JB Protein (product name: anti-HPV bioprotein dressing, registered trademark: Jinbo ®) has been approved in China to block high-risk HPV infection, reduce local viral load and prevent cervical lesions. Up to now, 4 SCI papers and more than 30 domestic clinical research papers have been published. Both clinical practice and research have confirmed that the JB Protein has a high negative conversion rate for HPV infection. In addition, JB protein does not affect human immunity, does not enter blood circulation, and thus is safe for clinical use. Since the listing of JB Protein in 2012, it has been used clinically in thousands of medical institutions in China, solving the problem of HPV infection in hundreds of thousands of women, and effectively reducing the incidence rate of cervical cancer in China. Under the guidance of the era strategy of "innovation-driven development", the development of new medical appliances for precision medicine has been included in the key development direction of the "Fourteenth Five-Year Plan" and the "Outline of Long-range Objectives Through the Year 2035". Jinbo Pharma said that since its establishment in 2008, the company has always adhered to the original innovation to lead the development of the enterprise. This time, Jinbo new functional protein-JB protein won the silver award at the 48th Geneva International Exhibition of Inventions, which is an encouragement and affirmation of the company's continuous efforts to innovate. In the future, Jinbo Pharma will continue to make efforts in the field of functional protein, continue to strive to become the bearer, leader and innovator of promoting the development of China's biomedical industry, realize the synchronous development of the enterprise and society, and make contributions to the cause of human health and beauty. It is understood that the Geneva International Exhibition of Inventions, founded in 1973 and jointly organized by the World Intellectual Property Organization and the Swiss Federal Government, is one of the world's longest, largest and most influential invention exhibitions. The awards of the Geneva Exhibition of Inventions are very strict. An international jury composed of more than 80 famous experts strictly reviews each participating invention project and selects some award-winning inventions. Due to the qualification and reputation of the jury, the awards are also widely recognized by countries around the world.